IMMP – Immutep Limited ADR
Immutep LimitedIMMP
$1.57Name : Immutep Limited
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $231,151,104.00
EPSttm : -0.21
Immutep Limited
$1.57
2.48%$0.04Float Short %
3.29
Margin Of Safety %
Put/Call OI Ratio
0.15
EPS Next Q Diff
EPS Last/This Y
-0.04
EPS This/Next Y
0.04
Price
1.61
Target Price
8.81
Analyst Recom
1.4
Performance Q
-25.81
Relative Volume
2.43
Beta
1.8
Ticker: IMMP
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-03-05 | IMMP | 1.8 | 0.14 | 0.00 | 3226 |
| 2025-03-06 | IMMP | 1.835 | 0.14 | 0.00 | 3220 |
| 2025-03-07 | IMMP | 1.75 | 0.14 | 0.00 | 3227 |
| 2025-03-10 | IMMP | 1.752 | 0.14 | 0.06 | 3244 |
| 2025-03-11 | IMMP | 1.73 | 0.13 | 0.33 | 3260 |
| 2025-03-12 | IMMP | 1.705 | 0.14 | 0.00 | 3261 |
| 2025-03-13 | IMMP | 1.74 | 0.13 | 1.33 | 3266 |
| 2025-03-14 | IMMP | 1.79 | 0.14 | 1.00 | 3276 |
| 2025-03-17 | IMMP | 1.81 | 0.13 | 0.00 | 3276 |
| 2025-03-18 | IMMP | 1.845 | 0.13 | 0.00 | 3278 |
| 2025-03-19 | IMMP | 1.89 | 0.13 | 0.00 | 3449 |
| 2025-03-20 | IMMP | 1.91 | 0.13 | 0.27 | 3453 |
| 2025-03-21 | IMMP | 1.9 | 0.13 | 0.00 | 3537 |
| 2025-03-24 | IMMP | 1.84 | 0.16 | 0.00 | 2977 |
| 2025-03-25 | IMMP | 1.85 | 0.15 | 0.00 | 3025 |
| 2025-03-26 | IMMP | 1.82 | 0.15 | 0.00 | 3098 |
| 2025-03-27 | IMMP | 1.83 | 0.15 | 17.00 | 3098 |
| 2025-03-28 | IMMP | 1.87 | 0.15 | 17.00 | 3098 |
| 2025-03-31 | IMMP | 1.77 | 0.15 | 0.00 | 3099 |
| 2025-04-01 | IMMP | 1.78 | 0.15 | 0.00 | 3099 |
| 2025-04-02 | IMMP | 1.68 | 0.15 | 0.00 | 3079 |
| 2025-04-03 | IMMP | 1.63 | 0.15 | 0.00 | 3065 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-03-05 | IMMP | 1.81 | - | - | -0.25 |
| 2025-03-06 | IMMP | 1.84 | - | -18.3 | -0.25 |
| 2025-03-07 | IMMP | 1.75 | - | -9.1 | -0.26 |
| 2025-03-10 | IMMP | 1.77 | - | -12.8 | -0.26 |
| 2025-03-11 | IMMP | 1.72 | - | -10.1 | -0.26 |
| 2025-03-12 | IMMP | 1.70 | - | -13.7 | -0.26 |
| 2025-03-13 | IMMP | 1.75 | - | -14.9 | -0.26 |
| 2025-03-14 | IMMP | 1.78 | - | -13.6 | -0.26 |
| 2025-03-17 | IMMP | 1.82 | - | -14.9 | -0.26 |
| 2025-03-18 | IMMP | 1.85 | - | -16.0 | -0.26 |
| 2025-03-19 | IMMP | 1.91 | - | -16.0 | -0.26 |
| 2025-03-20 | IMMP | 1.90 | - | -13.5 | -0.26 |
| 2025-03-21 | IMMP | 1.92 | - | -14.1 | -0.26 |
| 2025-03-24 | IMMP | 1.84 | - | -10.6 | -0.26 |
| 2025-03-25 | IMMP | 1.84 | - | -18.4 | -0.26 |
| 2025-03-26 | IMMP | 1.83 | - | -16.4 | -0.26 |
| 2025-03-27 | IMMP | 1.83 | - | -14.4 | -0.26 |
| 2025-03-28 | IMMP | 1.86 | - | -18.8 | -0.26 |
| 2025-03-31 | IMMP | 1.76 | - | -13.8 | -0.26 |
| 2025-04-01 | IMMP | 1.77 | - | -16.1 | -0.26 |
| 2025-04-02 | IMMP | 1.67 | - | -10.4 | -0.26 |
| 2025-04-03 | IMMP | 1.61 | - | -11.3 | -0.26 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-03-05 | IMMP | 0.00 | 45.55 | 3.52 |
| 2025-03-06 | IMMP | 0.00 | 45.55 | 3.52 |
| 2025-03-07 | IMMP | 0.00 | 45.55 | 3.52 |
| 2025-03-10 | IMMP | 0.00 | 45.15 | 3.52 |
| 2025-03-11 | IMMP | 0.00 | 45.15 | 3.52 |
| 2025-03-12 | IMMP | 0.00 | 45.15 | 3.49 |
| 2025-03-13 | IMMP | 0.00 | 45.15 | 3.49 |
| 2025-03-14 | IMMP | 0.00 | 45.15 | 3.49 |
| 2025-03-17 | IMMP | 0.00 | 45.03 | 3.49 |
| 2025-03-18 | IMMP | 0.00 | 45.03 | 3.49 |
| 2025-03-19 | IMMP | 0.00 | 45.03 | 3.49 |
| 2025-03-20 | IMMP | 0.00 | 45.03 | 3.49 |
| 2025-03-21 | IMMP | 0.00 | 45.03 | 3.49 |
| 2025-03-24 | IMMP | 0.00 | 44.37 | 3.49 |
| 2025-03-25 | IMMP | 0.00 | 44.37 | 3.49 |
| 2025-03-26 | IMMP | 0.00 | 44.37 | 3.29 |
| 2025-03-27 | IMMP | 0.00 | 44.37 | 3.29 |
| 2025-03-28 | IMMP | 0.00 | 44.37 | 3.29 |
| 2025-03-31 | IMMP | 0.00 | 49.86 | 3.29 |
| 2025-04-01 | IMMP | 0.00 | 49.86 | 3.29 |
| 2025-04-02 | IMMP | 0.00 | 49.86 | 3.29 |
| 2025-04-03 | IMMP | 0.00 | 49.86 | 3.29 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
Avg. EPS Est. Current Quarter
Avg. EPS Est. Next Quarter
Insider Transactions
Institutional Transactions
49.86
Beta
1.8
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
18
Growth Score
21
Sentiment Score
5
Actual DrawDown %
79.8
Max Drawdown 5-Year %
-72.9
Target Price
8.81
P/E
Forward P/E
PEG
P/S
P/B
2.19
P/Free Cash Flow
EPS
-0.22
Average EPS Est. Cur. Y
-0.26
EPS Next Y. (Est.)
-0.22
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
Relative Volume
2.43
Return on Equity vs Sector %
-45.2
Return on Equity vs Industry %
-32.4
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.01
EBIT Estimation
-11.3
Immutep LimitedSector: Healthcare
Industry: Biotechnology
Employees:
Immutep Limited, a late-stage biotechnology company, engages in developing novel LAG-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alpha (efti or IMP321), a soluble LAG-3lg fusion based, which is in clinical development for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma. In addition, it develops INSIGHT-003, which is in phase I to treat 1L NSCLC and solid tumors; INSIGHT-005, which is in phase I to treat metastatic urothelial cancer; IMP761, which is in preclinical trial to treat autoimmune disease; and IMP731 and IMP701 which is in clinical development. Further, the company develops LAG525, which is in phase II clinical trial to treat solid tumors and blood cancer, triple negative breast cancer, and melanoma; and in phase I to treat triple negative breast cancer. Immutep has collaboration with Merck & Co., Inc., GlaxoSmithKline, EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is based in Sydney, Australia.
stock quote shares IMMP – Immutep Limited ADR Stock Price stock today
news today IMMP – Immutep Limited ADR stock forecast ,stock prediction 2023 2024 2025
marketwatch IMMP – Immutep Limited ADR yahoo finance google finance
stock history IMMP – Immutep Limited ADR invest stock market
stock prices IMMP premarket after hours
ticker IMMP fair value insiders trading